Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussion with Amanda Wilhite, PA-C, of Houston Methodist Gastroenterology Associates. The episode explores how healthcare professionals may approach the two FDA-approved subcutaneous guselkumab maintenance dosing options for adults with moderate-to-severe Crohn’s disease and ulcerative colitis: 100 mg every eight weeks or 200 mg every four weeks. Drawing on data from the Phase 3 GALAXI 2 and 3 Crohn’s disease studies and the QUASAR ulcerative colitis maintenance study, Amy and Amanda discuss how disease severity, inflammatory burden, C-reactive protein levels, endoscopic response, previous advanced-therapy exposure, and individual patient needs may inform maintenance-dosing conversations. They also share real-world perspectives on monitoring treatment response and using the lowest effective recommended dosage to maintain therapeutic response. For additional IBD education, visit the GHAPP ACE app or digital hub.